Rasayanam Upgrades Ashwagandha KSM-66® Formula to Clinically Proven 600 mg Dosage

According to multiple clinical studies conducted over the past decade, a daily intake of 600 mg of KSM-66® Ashwagandha has been associated with improvements in stress management, sleep quality, recovery, and physical performance. Research has also indicated notable reductions in cortisol levels within eight weeks of consistent use.

While lower doses remain common across the supplement market, Rasayanam stated that the shift to 600 mg was made to ensure users receive a formulation more closely aligned with clinically validated outcomes.

A company spokesperson said the upgrade was introduced to bridge the gap between consumer expectations and scientifically supported efficacy.

“Today’s consumers are looking beyond marketing claims. They want wellness products backed by research and capable of delivering tangible results. The upgraded 600 mg formulation reflects our commitment to providing clinically aligned supplementation for long-term health and performance,” the spokesperson said.

The company also noted that while higher dosages exist, current research does not show significant additional benefits for most users beyond the 600 mg threshold. By adopting this dosage, Rasayanam aims to maintain a balance between effectiveness, safety, and suitability for daily use.

The upgraded supplement is designed to support individuals managing modern lifestyle challenges, including stress, fatigue, poor sleep, and recovery concerns. The company believes the move also represents a broader industry shift toward transparent, research-led wellness products.

Founded in 2020, Rasayanam Nutripharm Pvt. Ltd. focuses on clinically researched supplements with an emphasis on ingredient transparency, purity testing, and science-backed formulations.

About Rasayanam